Risk Factors for Infection in Patients with Remitted Rheumatic Diseases Treated with Glucocorticoids

被引:1
|
作者
Matsumoto, Yoshinori [1 ]
Sada, Ken-ei [1 ]
Takano, Mariko [1 ]
Toyota, Noriko [1 ]
Yamanaka, Ryutaro [1 ]
Sugiyama, Koichi [1 ]
Wakabayashi, Hiroshi [1 ]
Kawabata, Tomoko [1 ]
Otsuka, Fumio [1 ]
Makino, Hirofumi [1 ]
机构
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Med & Clin Sci, Okayama 7008558, Japan
关键词
infection; rheumatic disease; glucocorticoids; interstitial pneumonia; risk factors; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CRITICALLY ILL PATIENTS; HOSPITALIZED-PATIENTS; SERUM-ALBUMIN; CYTOMEGALOVIRUS; POPULATION; MORTALITY; CYCLOPHOSPHAMIDE; CORTICOSTEROIDS; COMPLICATIONS;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
It is well known that infection is one of the major causes of morbidity and mortality in rheumatic disease patients treated with high-dose glucocorticoids, especially in the early phase after achievement of disease remission. The aim of this study was to identify the risk factors for infection, with a focus on the dose of glucocorticoids administered, following the achievement of disease remission in rheumatic diseases patients. We retrospectively analyzed the medical records of rheumatic disease patients who had been treated with glucocorticoids. The primary endpoint was the incidence rate of infection during a period from 1 to 2 months after the commencement of treatment. From April 2006 to March 2010, 19 of 92 patients suffered from infection during the observation period. Age >= 65 yrs, presence of interstitial pneumonia, diagnosis of systemic vasculitis and serum creatinine level >= 2.0 mg/dl were found to be univariate predictors for infection. However, only the presence of interstitial pneumonia was an independent risk factor for infection (HR = 4.50, 95% CI = 1.65 to 14.44) by the Cox proportional hazard model. Even after achievement of clinical remission, careful observation is needed for patients with interstitial pneumonia, more so than for those receiving high-dose glucocorticoids.
引用
收藏
页码:329 / 334
页数:6
相关论文
共 50 条
  • [1] Risk Factors For Glucocorticoids-Induced Diabetes In Patients With Rheumatic Diseases.
    Katsuyama, Takayuki
    Aoki, Sayaka
    Sada, Ken-ei
    Yamamura, Yuriko
    Watanabe, Haruki
    Katsuyama, Eri
    Narazaki, Mariko
    Tatebe, Noriko
    Sugiyama, Koichi
    Watanabe, Katsue S.
    Wakabayashi, Hiroshi
    Kawabata, Tomoko
    Wada, Jun
    Makino, Hirofumi
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S873 - S874
  • [2] Risk factors for SARS-CoV-2 infection in patients with rheumatic diseases
    Snarska, Weronika
    Jurkowska, Zuzanna
    Bobrowska-Snarska, Danuta
    Brzosko, Marek
    Przepiera-Bedzak, Hanna
    [J]. POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2021, 131 (12):
  • [3] Cardiovascular risk factors in patients with rheumatic diseases
    Hernandez Batista, Sulema de la Caridad
    Villafuerte Morales, Johanna Elizabeth
    Chimbolema Mullo, Sergio Orlando
    Pilamunga Lema, Cesar Lenin
    [J]. REVISTA CUBANA DE REUMATOLOGIA, 2020, 22 (01):
  • [4] Amino Acid Profile in 18 Patients with Rheumatic Diseases Treated with Glucocorticoids and BCAAs
    Yoshikawa, Noritada
    Yamamoto, Motohisa
    Kuribara-Souta, Akiko
    Uehara, Masaaki
    Yamazaki, Hiroki
    Tanaka, Hirotoshi
    [J]. JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, 2021, 67 (03) : 180 - 188
  • [5] Clinical Utility of Trabecular Bone Score (TBS) in Fracture Risk Assessment of Patients with Rheumatic Diseases Treated with Glucocorticoids
    Nowakowska-Plaza, Anna
    Wronski, Jakub
    Sudol-Szopinska, Iwona
    Gluszko, Piotr
    [J]. HORMONE AND METABOLIC RESEARCH, 2021, 53 (08) : 499 - 503
  • [6] HOW EFFECTIVE ARE GLUCOCORTICOIDS IN PATIENTS WITH RHEUMATIC DISEASES?
    Nesterenko, V.
    Karateev, A.
    Makarov, M.
    Bialik, E.
    Makarov, S.
    Bialik, V.
    Nurmukhametov, M.
    Roskidailo, A.
    Filatova, E.
    Polishchuk, E.
    Khramov, A.
    Naryshkin, E.
    Glemba, K.
    [J]. AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (SUPPL 1) : S336 - S336
  • [7] Infection risk after orthopaedic surgery in patients with inflammatory rheumatic diseases treated with immunosuppressive drugs
    Scherrer, Catrina B.
    Mannion, Anne F.
    Kyburz, Diego
    Vogt, Markus
    Kramers-de Quervain, Ines A.
    [J]. SWISS MEDICAL WEEKLY, 2012, 142 : S2 - S2
  • [8] Infection Risk After Orthopedic Surgery in Patients With Inflammatory Rheumatic Diseases Treated With Immunosuppressive Drugs
    Scherrer, Catrina B.
    Mannion, Anne F.
    Kyburz, Diego
    Vogt, Markus
    Kramers-de Quervain, Ine S. A.
    [J]. ARTHRITIS CARE & RESEARCH, 2013, 65 (12) : 2032 - 2040
  • [9] Teriparatide treatment in osteoporotic patients treated with glucocorticoids for chronic inflammatory/autoimmune rheumatic diseases
    La Corte, R.
    Limpido, G.
    Volpinari, S.
    Trotta, F.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S324 - S324
  • [10] RISK FACTORS FOR POSTOPERATIVE COMPLICATIONS IN PATIENTS WITH RHEUMATIC DISEASES
    Herrera Van Oostdam, D. A.
    Garcia-Mosqueda, N.
    Abud-Mendoza, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 600 - 600